Tirzepatide emerges a groundbreaking treatment agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://adrealpzk542495.blogoscience.com/47250869/tirzepatide-a-game-changer-for-type-2-diabetes